ArticleInternational journal of chronic obstructive pulmonary disease2026
Efficacy and Safety of Dupilumab in Chronic Obstructive Pulmonary Disease with Type 2 Inflammation: A Single-Center Real-World Study.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy and safety of dupilumab combined with triple inhaled therapy in patients with chronic obstructive pulmonary disease (COPD) with type 2 inflammation in a real-world setting. Patients and Methods: This retrospective cohort study included patients with COPD and a type 2 inflammatory phenotype treated at the First Affiliated Hospital of Soochow University between October 2024 and December 2025. Propensity score matching (1:1) was performed to generate a study group receiving dupilumab plus triple therapy (ICS/LABA/LAMA) (n = 34) and a control group receiving triple therapy alone (n = 34). Pulmonary function, symptom scores, inflammatory biomarkers, acute exacerbations, and adverse events were assessed over 24 weeks. Results: After 24 weeks, improvements in pulmonary function, symptom burden, and airway inflammation were observed in patients receiving dupilumab combined with triple therapy. In the dupilumab group, FEV Conclusion: Dupilumab combined with triple inhaled therapy was associated with improvements in lung function, symptom burden, and airway inflammation in COPD patients with type 2 inflammation, with a favorable safety profile. A potential reduction in exacerbation risk was also observed, although further prospective studies are needed for confirmation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.